Home > Cardiology > Jury still out on value of screening for atrial fibrillation

Jury still out on value of screening for atrial fibrillation


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA
Reuters Health - 25/01/2022 - There remains insufficient evidence to gauge the benefits and harms of screening for atrial fibrillation in asymptomatic adults aged 50 and older, the U.S. Preventive Services Task Force (USPSTF) has concluded after an updated review. Atrial fibrillation is the most common type of cardiac arrhythmia and its prevalence increases with age, affecting about 10% of adults aged 85 and older. AF is a major risk factor for ischemic stroke. About one in five people are diagnosed with AF after suffering a stroke. Based on the latest evidence review, the task force determined there is not enough evidence to recommend for or against screening for AF, and therefore issued an "I" (insufficient evidence) statement. This recommendation applies to adults 50 years or older without a diagnosis of or symptoms of AF and without a history of transient ischemic attack or stroke. The updated recommendation matches the 2018 USPSTF recommendation o...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on